Pharvaris (NASDAQ:PHVS) Director Elisabeth Bjork Sells 52,500 Shares

Key Points

• Director Elisabeth Bjork sold 52,500 Pharvaris shares for approximately $1.99 million at an average price of $37.89, reducing her direct ownership by 77.59% to 15,167 shares.
• Pharvaris shares fell 1.0% to $36.02, while the company reported a quarterly loss of $0.81 per share—$0.06 worse than analysts’ expectations.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $59.87; 13 analysts rate the stock Buy, one Hold, and one Sell.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Elisabeth Bjork sold 52,500 shares of the firm's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the transaction, the director directly owned 15,167 shares in the company, valued at approximately $574,677.63. This represents a 77.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Pharvaris Trading Down 1.0%

NASDAQ PHVS traded down $0.35 on Monday, hitting $36.02. 653,689 shares of the company traded hands, compared to its average volume of 412,750. The business's 50 day moving average price is $35.37 and its 200-day moving average price is $31.75. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The company has a market capitalization of $2.36 billion, a price-to-earnings ratio of -11.81 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Analysts Set New Price Targets

PHVS has been the subject of several analyst reports. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Pharvaris in a report on Tuesday, September 8th. New Street Research set a $60.00 price target on shares of Pharvaris in a report on Friday, August 14th. Citigroup reiterated a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. Morgan Stanley increased their price objective on shares of Pharvaris from $46.00 to $62.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 9th. Finally, Citizens Jmp raised their price objective on shares of Pharvaris from $75.00 to $79.00 and gave the company a "market outperform" rating in a research report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $59.87.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new stake in shares of Pharvaris during the second quarter valued at approximately $41,000. CoreCap Advisors LLC bought a new position in shares of Pharvaris during the second quarter worth $93,000. Public Employees Retirement System of Ohio bought a new position in shares of Pharvaris during the second quarter worth $196,000. Algert Global LLC purchased a new position in Pharvaris during the second quarter valued at $238,000. Finally, Persistent Asset Partners Ltd purchased a new position in Pharvaris during the second quarter valued at $273,000.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.